Last $2.91 USD
Change Today -0.04 / -1.36%
Volume 35.0K
IMNP On Other Exchanges
As of 1:19 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

immune pharmaceuticals inc (IMNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - $5.65
52 Week Low
11/22/13 - $1.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immune pharmaceuticals inc (IMNP) Related Bloomberg News

View More Bloomberg News

immune pharmaceuticals inc (IMNP) Related Businessweek News

No Related Businessweek News Found

immune pharmaceuticals inc (IMNP) Details

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer. Its lead product candidate includes Bertilimumab, a human monoclonal antibody that is under Phase II clinical trial for the treatment of ulcerative colitis, as well as for the treatment of bullous pemphigoid, Crohn's disease, and severe asthma. The company’s product pipeline also comprise AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies that is under Phase III clinical trials; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors, which is under Phase I/II clinical trials. In addition, its preclinical stage product candidate includes anti-ferritin combination gemcitabine-paclitaxel NanomAbs for the treatment of pancreatic and non-small cell lung cancer. Immune Pharmaceuticals, Inc. has strategic partnerships with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Dalhousie University; and Shire Biochem, Inc. The company was founded in 2010 and is based in Cambridge, Massachusetts.

8 Employees
Last Reported Date: 04/28/14
Founded in 2010

immune pharmaceuticals inc (IMNP) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $112.7K
Compensation as of Fiscal Year 2013.

immune pharmaceuticals inc (IMNP) Key Developments

Immune Pharmaceuticals Inc. Initiates Phase II Clinical Trial In Ulcerative Colitis

Immune Pharmaceuticals Inc. announced that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). The Bertilimumab Phase II clinical trial is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult patients with active moderate to severe UC. Eligible patients will be randomly assigned in a 2:1 ratio to one of two treatment groups, bertilimumab 10 mg/kg or matching placebo, respectively. The study will consist of three periods: a screening period of up to two weeks, a four-week double-blind treatment period (three IV infusions over 30 minutes, at two-week intervals), and a safety and efficacy follow-up period of approximately nine weeks. Patient selection is based on elevated tissue eotaxin-1, a biomarker that has been shown to be associated with severity of disease in Bullous Pemphigoid, Ulcerative Colitis, Crohn's Disease, Severe Asthma and other conditions. Bertilimumab is a recombinant human IgG4 monoclonal antibody that neutralizes human eotaxin-1 (eotaxin).

Immune Pharmaceuticals, Inc. Approves Amendment to Certificate of Incorporation

Immune Pharmaceuticals, Inc. announced that its annual meeting of stockholders held on September 5, 2014 approved the amendment to the company's Certificate of Incorporation effecting a reverse stock split and declassifying the company's board of directors.

Immune Pharmaceuticals, Inc.(OTCPK:IMNP) added to NASDAQ Composite Index

Immune Pharmaceuticals, Inc. will be added to the NASDAQ Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMNP:US $2.91 USD -0.04

IMNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $0.72 USD -0.0237
View Industry Companies

Industry Analysis


Industry Average

Valuation IMNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,081.0x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,120.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at